Our Experience with the Use of Vasopressin in Hemodynamic Management of Shock and Outcome of Neonates

Abstract

These retrospective observational data were collected to understand the role of vasopressin in the hemodynamic management of neonates with shock in a tertiary-level NICU over a period of 2 years. This included 28 neonate who received vasopressin for different clinical states with hypotension like septic shock, MAS with PPHN, Sepsis with PPHN, PPHN with CDH, HOCM, and even in end-organ injury (AKI) with sepsis. The response to vasopressin was 78.5% with improved signs of shock. The overall mortality rate was 15%. This is an attempt to understand vasopressin use in very sick neonates. Randomized controlled trials are required for its use as a treatment protocol.